ProfileGDS5678 / 1419203_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 31% 31% 22% 33% 40% 33% 30% 31% 25% 30% 31% 45% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7462131
GSM967853U87-EV human glioblastoma xenograft - Control 22.6954431
GSM967854U87-EV human glioblastoma xenograft - Control 32.7040531
GSM967855U87-EV human glioblastoma xenograft - Control 42.4677222
GSM967856U87-EV human glioblastoma xenograft - Control 52.6964533
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0098640
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8121233
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6775530
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6791931
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5583825
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6826430
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6689831
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0691945
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6843430